The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women

Table 3 Unadjusted and Adjusted Regression Coefficient Estimates and 95% Confidence Intervals (CI) that Explain the mini-OQLQ for Patients With Incident Fractures Versus Those Without Incident Fractures^a.

Mini-OQLQ	Vertebral Fracture Group (I)				Non-Vertebral Fracture Group (II)
Domains	Estimates Unadjusted CI	(n)	Adjusted Estimates CI	(n)	Unadjusted Estimates CI	(n)	Adjusted Estimates CI	(n)
Total Score	-0.77	(699)	-0.86	(673)	-0.38	(737)	-0.47	(711)
	-1.22, -0.31		-1.30, -0.43		-0.62, -0.13		-0.70, -0.25
Symptoms	-0.70	(1755)	-0.76	(1214)	-0.17	(1847)	-0.25	(1295)
	-1.12, -0.29		-1.23, -0.30		-0.41, 0.07^c		-0.49, -0.01
Physical Functioning	-0.76	(1226)	-1.12	(1113)	-0.35	(1294)	-0.39	(1181)
	-1.20, -0.32		-1.57, -0.67		-0.62, -0.09		-0.65, -0.14
Emotional Functioning	-0.46	(1756)	-1.06	(1581)	-0.90	(1850)	-0.97	(1669)
	-0.85, -0.07		-1.44, -0.68		-1.13, -0.66		-1.20, -0.75
Activities of Daily Living	-1.13	(1290)	-1.47	(1116)	-0.41	(1365)	-0.47	(1188)
	-1.63, -0.63		-1.97, -0.96		-0.69, -0.14		-0.73, -0.21
Leisure	-0.81	(1038)	-0.92	(991)	0.08	(1087)	-0.05	(953)
	-1.29, -0.32		-1.37, -0.47		-0.22, 0.37^c		-0.32, 0.23^c

^aRegression coefficient estimates and 95% CI were calculated based on differences between the incident vertebral and incident non-vertebral fracture group versus the no fracture group (reference level: no incident fracture group) between pre and post HRQL measurements. The covariates included in the multiple regression analysis were group; baseline mini-OQLQ score; group by baseline mini-OQLQ score interaction; number of years between pre and post administration of the mini-OQLQ; age; baseline height; baseline weight; change in height (post-pre); prevalent vertebral and non-vertebral fracture status; number of prevalent vertebral and non-vertebral fractures; time spent exercising (hours/week); dietary calcium intake (g/day); baseline bone mineral density of the lumbar spine and femoral neck; medications such as bisphosphonates (etidronate or alendronate), estrogen, or others (calcitonin, fluoride or raloxifene); and co-morbidities (including heart attack; stroke; breast, ovarian, cervical, uterine and colon cancer and multiple myeloma; diabetes, epilepsy, arthritis, and thyroid disease). ^b (n) = sample size. ^c indicates a non significant differences between groups (the non-vertebral fracture group (II) versus the no fracture group (III)).

ISSN: 1471-2474